NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 µM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 µM and 2.53 µM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth[1].
Molecular Weight:
400.30
Formula:
C22H19Cl2NO2
Target:
Akt,Apoptosis,Caspase,CDK,Polo-like Kinase (PLK)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
